James Larkin

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

J. Larkin, M. Gore, M. Gore, 2011, British Journal of Cancer.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

J. Larkin, R. Plummer, P. Nathan, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

G. Stamp, M. Gore, G. Ricken, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.